#OCUL

1 month ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! Weekly Top Unu

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #FRMI 79% OTM
2. #OCUL 70% OTM
3. #CORZ 60% OTM
4. #VOYG 56% OTM
5. #NVTS 49% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 month ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #FRMI 79% OTM
2. #OCUL 70% OTM
3. #VOYG 56% OTM
4. #GME 46% OTM
5. #SOFI 41% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 month ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#FRMI, #OCUL, #VOYG, #GME, #RDDT

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 month ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! AM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #SATL 82% OTM
2. #CRWV 47% OTM
3. #AEVA 44% OTM
4. #HYMC 42% OTM
5. #OCUL 37% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 month ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#SATL, #CRWV, #AEVA, #HYMC, #OCUL

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 month ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! Weekly Top Unu

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #OCUL 97% OTM
2. #IMSR 95% OTM
3. #NB 72% OTM
4. #CCCX 52% OTM
5. #ALTS 51% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 month ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #OCUL 97% OTM
2. #CRDO 49% OTM
3. #RZLT 49% OTM
4. #SATL 47% OTM
5. #HOOD 41% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 month ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#OCUL, #CRDO, #RZLT, #SATL, #FRMI

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 month ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! Weekly Top Unu

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #OCUL 55% OTM
2. #NVTS 49% OTM
3. #IONQ 45% OTM
4. #SMCI 43% OTM
5. #SOGP 43% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 month ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #OCUL 55% OTM
2. #IONQ 48% OTM
3. #RGTI 44% OTM
4. #SMCI 43% OTM
5. #SOGP 43% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 month ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#OCUL, #IONQ, #SOGP, #SBET, #CTMX

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 month ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! AM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #RGTI 70% OTM
2. #OCUL 55% OTM
3. #SOGP 43% OTM
4. #SBET 41% OTM
5. #TSLA 30% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

@prismmarketview.bsky.social

1 month ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#OCUL, #SOGP, #SBET, #RR, #SVM

#OptionFlow #OptionsTrading #Trading

2 0 0 0

PRISM MarketView

1 month ago

Ocular Therapeutix Shares Rise on Renewed Sanofi Buyout Speculation Ocular Therapeutix (NASDAQ: OCUL) shares moved sharply higher following reports that Sanofi (NASDAQ: SNY) may be preparing a renewed acquisition bid for the oph

Ocular Therapeutix (NASDAQ: #OCUL) shares are climbing on renewed speculation that Sanofi (NASDAQ: #SNY) is preparing an increased takeover bid after the company reportedly rejected an earlier $16-per-share offer.
prismmarketview.com/ocular-thera...

0 0 0 0

Most Searched, Wednesday January 14, 2026 – Crystal Equity Research

2 months ago

Most searched small-cap stocks, Wed Jan 14th - #TE #RZLV #NVTS #RR #EVTV #IBRX #BNAI #FEED #SIDU #CLSK #XAIR #NXAP #ROLR #LAC #USAR #UAMY #OCUL #PLUG #CRML #AZI - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Most Searched, Monday January 12, 2026 – Crystal Equity Research

2 months ago

Most searched small-cap stocks, Mon Jan 12th - #SATL #LVLU #RXRX #DNN #CLSK #LAC #NVTX #RZLV #RDW #BTBT #BITF #BDSX #PLUG #UAMY #RR #OCUL #HYMC #EVRV #IBRX #ABAT - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Most Searched, Monday December 8, 2025 – Crystal Equity Research

3 months ago

Most searched small-cap stocks, Mon Dec 8th - #GPCR #FSLY #ABTC #TWG #JBLU #FULC #NVTS #DNN #OCUL #IRBT #BITF #PLUG #CETX #WVE #UUUU #USAR #PHR #ONDS #IDR #BBAI - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD Ocular Therapeutix (NASDAQ: OCUL) intends to submit an NDA for AXPAXLI in wet AMD shortly after positive year‑one SOL‑1 topline data, which are on track for 1Q 2026. The company plans to leverage the 505(b)(2) pathway and cites an existing SPA and a superiority trial design versus aflibercept to support an accelerated review. Ocular says AXPAXLI could be the first TKI commercialized for wet AMD with potential durability up to 12 months. The company will continue SOL‑1 into year two and run SOL‑R and SOL‑X to provide additional data for clinicians and payors.

3 months ago

#OCUL Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD

www.stocktitan.net/news/OCUL/ocular-therape...

0 0 0 0

Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR Ocular Therapeutix (NASDAQ: OCUL) announced the first patient randomized in HELIOS-3, the second Phase 3 registrational trial for AXPAXLI (OTX-TKI) in non-proliferative diabetic retinopathy (NPDR) on Nov 24, 2025. HELIOS-2 and HELIOS-3 are complementary global superiority studies using a novel ordinal ≥2-step diabetic retinopathy severity score (DRSS) primary endpoint, with primary assessment at Week 52. HELIOS-2 compares AXPAXLI dosed every 12 months to ranibizumab 0.3 mg; HELIOS-3 compares 6- and 12-month AXPAXLI regimens to sham. Ocular secured an SPA alignment with the FDA on the novel DRSS endpoint for HELIOS-2 and is targeting a broad DR label by including patients with non-center-involved DME (non-CI-DME).

3 months ago

#OCUL Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR

www.stocktitan.net/news/OCUL/ocular-therape...

0 0 0 0

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability Announced today that SOL-R achieved target randomization of 555 subjects Exceptional execution and retention in AXPAXLI wet AMD

4 months ago

#OCUL Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

www.stocktitan.net/news/OCUL/ocular-therape...

0 0 0 0

$475 Million Stock Offering: Ocular Therapeutix Raises Funds for Wet AMD Drug AXPAXLI Development Biotech firm to sell 37.9M shares at $12.53 each, funding AXPAXLI trials for wet AMD and diabetic retinopathy. Proceeds support manufacturing infrastructure and pre-commercialization activities.

5 months ago

#OCUL Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

www.stocktitan.net/news/OCUL/ocular-therape...

0 0 0 0

Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR Ocular Therapeutix (NASDAQ: OCUL) has secured FDA agreement under Special Protocol Assessment (SPA) for a registrational trial of AXPAXLI in non-proliferative diabetic retinopathy (NPDR). The agreement provides a clear regulatory pathway for AXPAXLI's development in diabetic eye disease.Phase 1 HELIOS trial results showed promising outcomes: no NPDR patients receiving AXPAXLI experienced disease progression or vision-threatening complications at 48 weeks, compared to 25% disease worsening and 40% vision-threatening complications in the control group. The treatment, designed for annual dosing, targets a significant market with nearly 9 million Americans affected by diabetic retinopathy.The company will present detailed clinical trial design, timing, and development strategy for NPDR and diabetic macular edema (DME) at its upcoming Investor Day on September 30, 2025.

7 months ago

#OCUL Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR

www.stocktitan.net/news/OCUL/ocular-therape...

0 0 0 0

Ocular Therapeutix Advances Only Superiority Trial in Wet AMD, Reports $391M War Chest Through 2028 First-ever superiority trial in wet AMD progressing with exceptional patient retention. Q2 results reveal strong $391M cash position. See timeline for potential market disruption.

7 months ago

#OCUL Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights

www.stocktitan.net/news/OCUL/ocular-therape...

0 0 0 0

8 months ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#BBAI, #CORZ, #OCUL, #OKLO, #SNAP

#OptionFlow #OptionsTrading #Trading

0 0 0 0

Ocular Therapeutix Pivots to $14B Retina Market with Revolutionary AMD Treatment Platform Breakthrough retina-focused strategy targets 1.8M AMD patients. AXPAXLI therapy aims to reduce 12 yearly injections to just one. See how this transforms eye care.

8 months ago

#OCUL Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

www.stocktitan.net/news/OCUL/ocular-therape...

0 0 0 0